Mitral Valve Regurgitation

Mitral valve regurgitation describes the malfunctioning of the mitral valve, allowing the backflow of blood into the left atrium during heart contraction.

The mitral valve is a dual-flap valve in the heart that is located between the left atrium and the left ventricle. During diastole, a normally-functioning mitral valve opens as a result of increased pressure from the left atrium as it fills with blood. As atrial pressure increases above that of the left ventricle, the mitral valve opens. Opening facilitates the passive flow of blood into the left ventricle. Diastole ends with atrial contraction. The mitral valve closes at the end of atrial contraction to prevent a reversal of blood flow.

A malfunction of the mitral valve can be caused by elongated or ruptured Chordae Tendineae. The heart compensates for this inefficient pumping by progressively enlarging, which eventually results in heart failure. Mitral insufficiency is the most common form of valvular heart disease.

According to the Cleveland clinic and the American Heart Association mitral valve regurgitation occurs in about 2-3% of the world’s population. Every year about 250’000 patients are newly diagnosed with it worldwide.

The current “Golden Standard” treatment

The current “Gold Standard” treatment is the surgical repair of the broken chords, which requires an open-heart surgery at arrested heart with the help of a heart-lung machine.

This treatment leads to good results but still leaves a number of challenges like:

Technology

ChordArt™, the CoreMedic Solution

CoreMedic is developing advice that is addressing a number of unmet needs compared to the surgical “Gold Standard” treatment - the “ChordArt” trans-femoral, transseptal catheter system”.

The basic concept consists of an implant that is used to replace the ruptured or elongated chordae of the valve and re-establishes the connection of the leaflet of the valve with the papillary muscle to restore the proper function.

CoreMedic is developing a transcatheter System that facilitate the safe and efficient delivery and deployment of the implant. – The ChordArt TM Transcatheter System.

ChordArt™

is taking the treatment to a next level by reducing the invasiveness of the procedure. The goal is to allow for the valve repair to be carried out via the vascular route through a tiny incision in the groin, by trans-septal approach to the mitral valve, all the while performing the procedure on the beating heart without the need of a heart lung machine.

This allows for a dramatically less traumatic treatment, leading to fewer risks for the patient, a faster recovery and results in heart failure.

ChordArt™

is taking the treatment to a next level by reducing the invasiveness of the procedure. The goal is to allow for the valve repair to be carried out via the vascular route through a tiny incision in the groin, by trans-septal approach to the mitral valve, all the while performing the procedure on the beating heart without the need of a heart lung machine.

This allows for a dramatically less traumatic treatment, leading to fewer risks for the patient, a faster recovery and results in heart failure.

The ChordArt™ Advantages:

About Us

CoreMedic is focusing on the development of devices and therapies to address the treatment of heart valve diseases. CoreMedic AG has emerged out of the orbit of the University Hospital of Berne), a world leading hospital regarding the development of new technologies and treatment methods in the areas of Cardiology and Cardiac Surgery.

Facts of the company:

Investors

For Business Development and Investor inquiry please contact Thomas Bauer at

thomas.bauer@coremedic.ch

Management Board / Clinical Advisor

Thomas Bauer, Dipl- Ing (FH), MBA (CEO)

Thomas Bauer a professional in the health care industy.

He is experienced in leading multifunctional and multinational teams in start-up, medium to small business as well as multinational corporations. He has a proven track record in research and development of medical devices in and for highly regulated environments, strong background in engineering, operations, quality management systems, risk management and regulatory affairs.Companies: Hexal, Jomed, Abbott, Invatec, Medtronic.

Alberto Weber, PD Dr. med. (CMO, scientific and clinical advisor)

Dr. med. Weber is one of the “fathers” of the ChordArt idea.

He is a cardiovascular surgeon by training and moved from the Inselspital Bern, via the University Hospital Zurich (USZ) to Herzzentrum Hirslanden in Zurich in 2018. Dr. Weber participated and supported numerous medical device ideas at the ARTORG center in Bern, a translational center where ideas from the clinical environment are being investigated and developed. He functioned both as clinical/ scientific expert and inventor himself. He is performing hundreds of surgical treatments and procedures every year.

Prof. Rolf Vogel. MD, PhD, MSEE (scientific and clinical advisor)

Prof. Vogel is both, an engineer and cardiologist by training.

He has been and is participating in multiple projects with regards to medical device development at the ARTORG center in Bern and the University of Applied Sciences in Bern/ Biel. He is supporting and driving a lot of developments and device ideas from feasibility to actual development.

Thierry Carrel, Prof. Dr. med. (scientific and clinical advisor)

Prof. Carrel is a well-known and respected heart and vascular surgeon.

He has been and is involved in a large number of sciences and medical device projects both as active member and as chairman of multiple funding and scientific organizations. He theses and supported hundreds of publications as well as bachelor, master and doctoral theses. He is member of multiple scientific societies and sits on editorial boards for several scientific journals and medical publications.

NEWS

News on Linkedin
Follow Us On
2020

May

2 year follow-up of ChordArt S Clinical Study CHAGALL

2019

May

Publication: Automated Implantation of Artificial Mitral Chords: Preliminary Results From Feasibility Trail

https://www.annalsthoracicsurgery.org/article/S0003-4975(19)31425-0/fulltext

2018

April

CoreMedic announces first clinical use of mitral valve chordal repair system ChordArt™more (PDF download)
http://www.coremedic.ch/fileadmin/user_upload/Press_Release_CoreMedic_First_In_Man_Study_May2018.pdf